Perrigo Company plc (NYSE:PRGO) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in shares of Perrigo Company plc (NYSE:PRGO) by 2.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 70,216 shares of the company’s stock after selling 1,850 shares during the period. Mutual of America Capital Management LLC owned 0.05% of Perrigo worth $1,969,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Perrigo by 6,828.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,845,539 shares of the company’s stock worth $201,710,000 after purchasing an additional 7,732,309 shares during the period. Norges Bank purchased a new position in shares of Perrigo in the 4th quarter worth about $36,614,000. Ion Asset Management Ltd. raised its holdings in shares of Perrigo by 50.1% in the 4th quarter. Ion Asset Management Ltd. now owns 2,820,000 shares of the company’s stock worth $72,502,000 after purchasing an additional 941,667 shares during the period. BW Gestao de Investimentos Ltda. raised its holdings in shares of Perrigo by 111.6% in the 4th quarter. BW Gestao de Investimentos Ltda. now owns 1,097,192 shares of the company’s stock worth $28,209,000 after purchasing an additional 578,597 shares during the period. Finally, Boone Capital Management LLC raised its holdings in shares of Perrigo by 126.1% in the 4th quarter. Boone Capital Management LLC now owns 1,022,369 shares of the company’s stock worth $26,285,000 after purchasing an additional 570,148 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Trading Down 0.7%

Shares of NYSE PRGO opened at $26.95 on Friday. The company has a market cap of $3.71 billion, a price-to-earnings ratio of -20.57 and a beta of 0.45. Perrigo Company plc has a 12-month low of $23.14 and a 12-month high of $30.93. The company has a current ratio of 2.36, a quick ratio of 1.28 and a debt-to-equity ratio of 0.82. The stock’s 50 day simple moving average is $26.82 and its 200 day simple moving average is $26.13.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.04. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the business earned $0.29 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. Equities research analysts expect that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th were paid a $0.29 dividend. The ex-dividend date of this dividend was Friday, May 30th. This represents a $1.16 dividend on an annualized basis and a yield of 4.30%. Perrigo’s dividend payout ratio (DPR) is currently -88.55%.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Perrigo from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $33.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.